Form 4: Spruce Biosciences Director Aynechi Tiba Acquires 30,000 Stock Options

Director Aynechi Tiba of Spruce Biosciences acquired 30,000 stock options on May 22, 2024, at an exercise price of $0.7511.

Summary

• On May 22, 2024, Aynechi Tiba, a director of Spruce Biosciences, acquired 30,000 stock options.
• The exercise price for these options is $0.7511 per share.
• The options vest on the first anniversary of the grant date or fully vest by the date of the company's 2025 annual stockholder meeting, contingent upon continuous service.
• Full vesting also occurs upon a Change in Control as defined in the 2020 Equity Incentive Plan.
• The options expire on May 21, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but the filing itself is a standard regulatory disclosure.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to continued service and a potential change in control, suggesting a focus on long-term commitment and strategic events.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates